NCT04497168CompletedPhase 2
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- First submitted
- 29 Jul 2020
- Start date
- 1 Apr 2021
- Primary completion date
- 2 Mar 2026
- Lead sponsor
- University of Michigan
- Diseases
- Parkinson disease
- NCT number
- NCT04497168
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 58
- From 1 Apr 2021 to the primary completion date, 2 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to participate in research procedures involving ionizing radiation
- Subjects taking certain contraindicated medications at baseline
- Subjects with a previous history of mania, ongoing hepatic impairment or epilepsy
Other illness
- Diagnosis of an atypical parkinsonian condition
- Participants on neuroleptics and participants with a history of use of anti-depressants (including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), bupropion, St. John's Wort or other serotoninergic agents in the year preceding study enrollment
- Evidence of a large artery stroke or mass lesion on brain imaging
- Participants with a life threatening comorbid illness
- Subjects with a known allergy to citalopram or escitalopram
- Subjects with substantial cognitive impairment or dementia that would prevent them from providing informed consent
- Subjects with treatment-naieve Parkinson disease
Lab values
- Participants with a QTc interval on baseline EKG \>0.45 for men or \>0.47 for women
Other
- Severe claustrophobia precluding PET imaging
- Pregnancy or breastfeeding
- Participants with active depression as defined by a Geriatric Depression Scale score of \>10 or on the basis of clinical diagnosis by the PI
- Participants who report active suicidal ideation as defined by an affirmative answer to questions 1 and 2 on the C-SSRS
- Participants with baseline HY scores \<2.0 or ≥3.0
- Subjects unable to swallow pills
- Subjects in another ongoing clinical trial
Who the study is looking for
- Subjects with a Parkinson Disease (PD) diagnosis based on the United Kingdom Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria
- Modified Hoehn and Yahr (HY) scores spanning 2.0 to 3.0
- Age 65 years or greater
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.